In a significant development for the field of neuroscience, Addex Therapeutics has announced the publication of robust preclinical findings concerning ADX71743, a highly selective negative allosteric modulator (NAM) of the metabotropic glutamate receptor 7 (mGlu7). The study, published in the International Journal of Neuropsychopharmacology, offers a deep dive into how mGlu7 modulation acts as a biological "switch" for sleep-wake regulation and the body’s complex neurochemical response to stress.
By successfully demonstrating that ADX71743 can significantly alter wakefulness and modulate neurotransmitters in stress-responsive brain regions, the research provides a critical foundation for future pharmacological interventions. This discovery, now being advanced under the umbrella of Neurosterix—a company born from Addex’s innovative research pipeline—positions mGlu7 as a primary therapeutic target for a spectrum of central nervous system (CNS) disorders, including PTSD, anxiety, and various mood-related illnesses.
The Main Facts: Decoding the mGlu7 Mechanism
The core of this breakthrough lies in the precise, targeted nature of ADX71743. Unlike traditional pharmacological agents that may impact broad neural pathways, resulting in systemic side effects, ADX71743 functions as a negative allosteric modulator. This means it fine-tunes the activity of the mGlu7 receptor rather than simply "blocking" it.
The mGlu7 receptor is a G-protein-coupled receptor primarily located at the presynaptic terminals of neurons, where it plays a critical role in controlling neurotransmitter release. By modulating this receptor, researchers have identified a way to influence sleep architecture and stress pathways without the off-target complications often seen in earlier generations of CNS drugs. The findings suggest that by inhibiting mGlu7 activity, researchers can "upregulate" wakefulness and suppress REM and NREM sleep, offering a potential path to treating disorders characterized by excessive lethargy or dysregulated circadian rhythms.
Chronology of Discovery: From Laboratory to Publication
The journey of ADX71743 represents years of rigorous scientific inquiry. Addex Therapeutics, known for its expertise in allosteric modulation, initially identified mGlu7 as a high-value target due to its distribution in brain regions critical for emotional processing and arousal, such as the hippocampus and amygdala.
- Early Discovery Phase: Scientists at Addex screened thousands of compounds to identify a molecule with the specific binding affinity required to act as a selective NAM for mGlu7. ADX71743 emerged as the lead candidate due to its pharmacokinetic profile and its ability to cross the blood-brain barrier effectively.
- In Vivo Validation: Following initial laboratory success, the team moved to in vivo models, specifically using rat subjects to monitor sleep-wake cycles and neurotransmitter flux.
- Neurochemical Mapping: Researchers conducted longitudinal studies to track the real-time response of glutamate, GABA, and monoamines in the ventral hippocampus when the animal was exposed to controlled stressors.
- Peer Review and Publication: The culmination of this multi-year effort was the submission and subsequent peer-reviewed publication in the International Journal of Neuropsychopharmacology. This milestone serves as the "gold standard" validation, signaling to the global scientific community that the findings are scientifically sound and replicable.
- Strategic Transition: As part of a broader corporate strategy, the mGlu7 program—including the ADX71743 asset—was transitioned to Neurosterix, a spin-off entity focused on accelerating the development of allosteric modulators for psychiatric and neurological conditions.
Supporting Data: Quantitative Insights into Sleep and Stress
The data provided by the study is striking, particularly regarding the potency of ADX71743 in altering basic sleep architecture. In controlled laboratory trials, the administration of the compound yielded the following results:
- Wakefulness Enhancement: Subject animals experienced an increase in wakefulness of up to 100%. This suggests that the modulation of the mGlu7 receptor is a potent driver of arousal.
- Sleep Suppression: The compound acted as a robust inhibitor of sleep phases, with REM sleep reduced by up to 100% and NREM sleep reduced by up to 75% in the observed cohorts.
- Temporal Delay: Perhaps most importantly for potential clinical use, the compound effectively delayed the onset of both REM and NREM sleep by nearly two-fold for a two-hour window post-dosing.
- Stability of Biological Markers: Crucially, these sleep modifications occurred without significantly altering body temperature or motor activity. This is a vital distinction; many wake-promoting agents (such as amphetamines) trigger "jitteriness" or hyper-locomotion. The fact that ADX71743 maintains motor stability suggests a cleaner safety profile.
Regarding neurochemistry, the study observed that ADX71743 significantly attenuated stress-induced fluctuations in GABA and serotonin. In the ventral hippocampus—the "emotional hub" of the brain—treated animals showed higher, more stable levels of these neurotransmitters compared to control groups. This indicates that the drug helps the brain maintain a "homeostatic" state even when faced with environmental stressors, effectively acting as a buffer against the neurochemical chaos typically triggered by fear or anxiety.
Official Responses and Industry Perspectives
The leadership at Addex Therapeutics has expressed significant optimism regarding the implications of these findings. Tim Dyer, CEO of Addex, emphasized that the study is more than just a successful experiment; it is a validation of the entire mGlu7 therapeutic platform.
"This publication demonstrating the role of mGlu7 modulation in sleep and wakefulness adds another important piece of evidence supporting the therapeutic potential of targeting these receptors with allosteric modulation," Dyer stated in a recent press release. He further noted that ADX71743 has been instrumental in establishing the biological relevance of mGlu7 across multiple disease models.
For the scientific community, this data serves as a bridge. It moves the conversation about mGlu7 from theoretical potential to tangible drug development. By providing clear evidence that the receptor governs complex behaviors like sleep and stress response, Addex and Neurosterix have successfully de-risked the program for future investment and clinical trial progression.
Implications: The Future of CNS Therapy
The implications of this research are far-reaching. Currently, the landscape for treating PTSD, severe anxiety, and sleep disorders is crowded with drugs that often carry heavy side-effect burdens, including addiction potential, daytime grogginess, and metabolic disruption.
1. A New Paradigm for PTSD
Patients suffering from PTSD often experience hyper-arousal and fragmented sleep. By stabilizing the neurochemical environment of the ventral hippocampus, ADX71743 could theoretically provide a way to "dampen" the overactive stress response that characterizes the disorder, without the need for traditional benzodiazepines or sedatives.
2. Precision Psychiatry
The specificity of ADX71743 is a hallmark of "precision psychiatry." Because it targets an allosteric site rather than the primary orthosteric site, it allows for a more subtle modulation of the receptor. This means that if a patient has a specific neurochemical imbalance, the drug works in harmony with the body’s natural signaling rather than overriding it.
3. The Shift to Allosteric Modulation
The success of this program reinforces the growing trend of favoring allosteric modulators over traditional antagonists or agonists. This pharmaceutical strategy is becoming the preferred route for developers looking to create drugs that are both effective and tolerable for long-term use.
4. Broadening the Pipeline
With the mGlu7 program now firmly housed within Neurosterix, the focus will likely shift toward human clinical trials. While preclinical models in rats are a critical step, the next phase will involve determining safety and efficacy in humans, optimizing dosing schedules, and exploring how this mechanism interacts with other neurotransmitter systems in the human brain.
Conclusion
The recent publication regarding ADX71743 is a watershed moment for the mGlu7 research program. By mapping the clear, quantifiable effects of this modulator on sleep-wake regulation and stress-related neurochemistry, Addex Therapeutics and Neurosterix have provided the scientific community with a compelling roadmap for the future.
As we look toward the horizon of neuropsychopharmacology, the ability to selectively modulate the brain’s glutamate systems offers a promising new weapon against the debilitating effects of stress-related disorders. While the transition from preclinical success to human clinical application is a path fraught with challenges, the strength of the data published in the International Journal of Neuropsychopharmacology suggests that we are closer than ever to unlocking the therapeutic potential of the mGlu7 receptor. For patients living with the daily weight of mood and anxiety disorders, this research represents not just a scientific victory, but a genuine hope for a new generation of targeted, effective, and tolerable treatments.
